Advertisement

Zibb

Ed SperlingOffering news and business analysis for the design engineer, Managing News Editor Suzanne Deffree filters the electronics industry's developments and trends to explain how what's happening in the board room today can impact the tech innovation of tomorrow. Follow Suzanne on Twitter, @Deffree. Suzanne also manages EDN's Twitter account, @EDNMagazine.



   Advertisement

Profile

RSS Feed

  • Add this blog to your RSS newsreader!

Recent Posts

Recent Comments

Most Commented On

Archives

By Category

News Center Articles

Blog

Thursday, January 22, 2009

Jobs health problems reportedly spur SEC review of Apple

Jan 22 2009 10:34AM | Permalink |Comments (3) |


Apparently questions as to whether Steve Jobs' health issues are a private or public matter have been answered.

The SEC (Securities and Exchange Commission) is reportedly reviewing Apple's disclosures about the CEO's health problems to make certain that investors were not misled and that the company's stock was not falsely impacted.

The subject of private versus public matters and stock price has been commented on by many of this blog's readers, most of which disagree with Job's stance that his health is a private matter. As Apple is a public company and as he is the well-known face of that company, many believe Jobs' ability to run Apple will affect its ability to produce innovative products.

If you watch the company's stock, AAPL, it's easy to see why reader opinion leans that way. After rumors on Jobs health trashed AAPL in late 2008, the pancreatic cancer survivor on January 5 reluctantly stated that a "hormone imbalance" has been "robbing" his body of the proteins it needs to be healthy and has caused the beloved tech industry exec's very noticeable and rapid weight loss. At that time, he said he would continue to lead Apple through his recuperation period, expected to conclude in the spring. And, with the popular techie stating he'd continue to steer Apple, AAPL climbed about 4% that day to $94.58. 

Then, after market close on January 14, Jobs stated that his health issues were "more complex than originally thought" and that he would be taking a medical leave of absence, putting Apple COO Tim Cook in charge.  Surprise, surprise, AAPL fell from January 14's close of $85.33 to $83.33 on January 15, and has been on a downward slope since then, closing at $82.83 yesterday afternoon.

Apple's stellar earnings report came out after market close Tuesday and has been driving the stock back up, however. The company has Wall Street watchers impressed with its posted record revenue of $10.17 billion and record net quarterly profit of $1.61 billion, or $1.78 per diluted share, in this economic environment. AAPL was up 5.82% as of 12:09pm eastern today to $87.65.

The SEC has yet to release a statement on the reported review of Apple and Apple has also not commented. But what are your comments? Would such an SEC review be justified? Should Jobs continue his fight to keep his health matters private? Does Apple owe its stockholders more information? Voice your opinion below.


Reader Comments



at 1/22/2009 1:47:29 PM, txgordo said:
It seems to me the SEC would have bigger fish to fry - what a waste of time and taxpayer dollars!



at 1/22/2009 3:54:36 PM, KingMel said:
There have been much greater movements in AAPL share price related to false announcements (Steve Job's obituary) and unfounded speculation (medical opinions from analysts and doctors who were not familiar with Job's case, much less involved in his diagnosis and treatment).

Unless it is proven that Job's issued a false statement regarding his health (the hormone imbalance), this is a non-issue.

Reinstitute the uptick rule and rein in the analyst/trader corruption.



at 1/27/2009 9:20:04 AM, Kengilleo said:
Apple is still a shining star, all my Apple products work great, 10's of thousands of bright people work there, so what's the problem? In the meantime, the news shows a parade of crooks that slipped through the system.

Post a comment



Display Name

Change Image
Before submitting this form, please type the characters displayed above.
Note the letters are NOT case sensitive.


ADVERTISEMENT

©1997-2010 Reed Business Information, a division of Reed Elsevier Inc. All rights reserved.
Use of this Web site is subject to its Terms of Use | Privacy Policy